Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Impact of persistent PSA after salvage radical prostatectomy: a multicenter study

F. Preisser, RB. Incesu, P. Rajwa, M. Chlosta, F. Nohe, M. Ahmed, AL. Abreu, G. Cacciamani, L. Ribeiro, A. Kretschmer, T. Westhofen, JA. Smith, T. Steuber, G. Calleris, Y. Raskin, P. Gontero, S. Joniau, R. Sanchez-Salas, SF. Shariat, I. Gill, RJ....

. 2024 ; 27 (4) : 686-692. [pub] 20231006

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25003354
E-zdroje Online Plný text

NLK ProQuest Central od 2000-07-01 do Před 1 rokem
Open Access Digital Library od 1997-01-01
Health & Medicine (ProQuest) od 2000-07-01 do Před 1 rokem
Public Health Database (ProQuest) od 2000-07-01 do Před 1 rokem

Odkazy

PubMed 37803241
DOI 10.1038/s41391-023-00728-5
Knihovny.cz E-zdroje

BACKGROUND AND OBJECTIVE: Persistent prostatic specific antigen (PSA) represents a poor prognostic factor for recurrence after radical prostatectomy (RP). However, the impact of persistent PSA on oncologic outcomes in patients undergoing salvage RP is unknown. To investigate the impact of persistent PSA after salvage RP on long-term oncologic outcomes. MATERIAL AND METHODS: Patients who underwent salvage RP for recurrent prostate cancer between 2000 and 2021 were identified from twelve high-volume centers. Only patients with available PSA after salvage RP were included. Kaplan-Meier analyses and multivariable Cox regression models were used to test the effect of persistent PSA on biochemical recurrence (BCR), metastasis and any death after salvage RP. Persistent PSA was defined as a PSA-value ≥ 0.1 ng/ml, at first PSA-measurement after salvage RP. RESULTS: Overall, 580 patients were identified. Of those, 42% (n = 242) harbored persistent PSA. Median follow-up after salvage RP was 38 months, median time to salvage RP was 64 months and median time to first PSA after salvage RP was 2.2 months. At 84 months after salvage RP, BCR-free, metastasis-free, and overall survival was 6.6 vs. 59%, 71 vs. 88% and 77 vs. 94% for patients with persistent vs. undetectable PSA after salvage RP (all p < 0.01). In multivariable Cox models persistent PSA was an independent predictor for BCR (HR: 5.47, p < 0.001) and death (HR: 3.07, p < 0.01). CONCLUSION: Persistent PSA is common after salvage RP and represents an independent predictor for worse oncologic outcomes. Patients undergoing salvage RP should be closely monitored after surgery to identify those with persistent PSA.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003354
003      
CZ-PrNML
005      
20250206104302.0
007      
ta
008      
250121s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41391-023-00728-5 $2 doi
035    __
$a (PubMed)37803241
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Preisser, Felix $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg Eppendorf, Hamburg, Germany $u Department of Urology, University Hospital Frankfurt, Frankfurt, Germany
245    10
$a Impact of persistent PSA after salvage radical prostatectomy: a multicenter study / $c F. Preisser, RB. Incesu, P. Rajwa, M. Chlosta, F. Nohe, M. Ahmed, AL. Abreu, G. Cacciamani, L. Ribeiro, A. Kretschmer, T. Westhofen, JA. Smith, T. Steuber, G. Calleris, Y. Raskin, P. Gontero, S. Joniau, R. Sanchez-Salas, SF. Shariat, I. Gill, RJ. Karnes, P. Cathcart, H. Van Der Poel, G. Marra, D. Tilki
520    9_
$a BACKGROUND AND OBJECTIVE: Persistent prostatic specific antigen (PSA) represents a poor prognostic factor for recurrence after radical prostatectomy (RP). However, the impact of persistent PSA on oncologic outcomes in patients undergoing salvage RP is unknown. To investigate the impact of persistent PSA after salvage RP on long-term oncologic outcomes. MATERIAL AND METHODS: Patients who underwent salvage RP for recurrent prostate cancer between 2000 and 2021 were identified from twelve high-volume centers. Only patients with available PSA after salvage RP were included. Kaplan-Meier analyses and multivariable Cox regression models were used to test the effect of persistent PSA on biochemical recurrence (BCR), metastasis and any death after salvage RP. Persistent PSA was defined as a PSA-value ≥ 0.1 ng/ml, at first PSA-measurement after salvage RP. RESULTS: Overall, 580 patients were identified. Of those, 42% (n = 242) harbored persistent PSA. Median follow-up after salvage RP was 38 months, median time to salvage RP was 64 months and median time to first PSA after salvage RP was 2.2 months. At 84 months after salvage RP, BCR-free, metastasis-free, and overall survival was 6.6 vs. 59%, 71 vs. 88% and 77 vs. 94% for patients with persistent vs. undetectable PSA after salvage RP (all p < 0.01). In multivariable Cox models persistent PSA was an independent predictor for BCR (HR: 5.47, p < 0.001) and death (HR: 3.07, p < 0.01). CONCLUSION: Persistent PSA is common after salvage RP and represents an independent predictor for worse oncologic outcomes. Patients undergoing salvage RP should be closely monitored after surgery to identify those with persistent PSA.
650    _2
$a lidé $7 D006801
650    12
$a prostatektomie $x metody $7 D011468
650    _2
$a mužské pohlaví $7 D008297
650    12
$a prostatický specifický antigen $x krev $7 D017430
650    12
$a záchranná terapie $7 D016879
650    12
$a nádory prostaty $x chirurgie $x patologie $x krev $x mortalita $7 D011471
650    _2
$a senioři $7 D000368
650    _2
$a lidé středního věku $7 D008875
650    12
$a lokální recidiva nádoru $x patologie $x chirurgie $x krev $7 D009364
650    _2
$a prognóza $7 D011379
650    _2
$a následné studie $7 D005500
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a nádorové biomarkery $x krev $7 D014408
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Incesu, Reha-Baris $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg Eppendorf, Hamburg, Germany
700    1_
$a Rajwa, Pawel $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, Medical University of Silesia, Zabrze, Poland $1 https://orcid.org/0000000340736584
700    1_
$a Chlosta, Marcin $u Department of Urology, Medical University of Vienna, Vienna, Austria
700    1_
$a Nohe, Florian $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg Eppendorf, Hamburg, Germany
700    1_
$a Ahmed, Mohamed $u Department of Urology, Mayo Clinic, Rochester, MN, USA
700    1_
$a Abreu, Andre Luis $u Keck Medical Center of USC, USC Institute of Urology, University of Southern California, Los Angeles, CA, USA $1 https://orcid.org/0000000291672587
700    1_
$a Cacciamani, Giovanni $u Keck Medical Center of USC, USC Institute of Urology, University of Southern California, Los Angeles, CA, USA
700    1_
$a Ribeiro, Luis $u Urology Centre, Guy's Hospital, London, UK
700    1_
$a Kretschmer, Alexander $u Department of Urology, Ludwig-Maximilians University of Munich, Munich, Germany
700    1_
$a Westhofen, Thilo $u Department of Urology, Ludwig-Maximilians University of Munich, Munich, Germany
700    1_
$a Smith, Joseph A $u Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA
700    1_
$a Steuber, Thomas $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg Eppendorf, Hamburg, Germany
700    1_
$a Calleris, Giorgio $u Department of Surgical Sciences, San Giovanni Battista Hospital and University of Turin, Turin, Italy $1 https://orcid.org/0000000338311632
700    1_
$a Raskin, Yannic $u Department of Urology, University Hospitals Leuven, Leuven, Belgium
700    1_
$a Gontero, Paolo $u Department of Surgical Sciences, San Giovanni Battista Hospital and University of Turin, Turin, Italy
700    1_
$a Joniau, Steven $u Department of Urology, University Hospitals Leuven, Leuven, Belgium $1 https://orcid.org/0000000331959890
700    1_
$a Sanchez-Salas, Rafael $u Department of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan $u Department of Urology, Weill Cornell Medical College, New York, NY, USA $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA
700    1_
$a Gill, Inderbir $u Keck Medical Center of USC, USC Institute of Urology, University of Southern California, Los Angeles, CA, USA
700    1_
$a Karnes, R Jeffrey $u Department of Urology, Mayo Clinic, Rochester, MN, USA
700    1_
$a Cathcart, Paul $u Urology Centre, Guy's Hospital, London, UK
700    1_
$a Van Der Poel, Henk $u Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands
700    1_
$a Marra, Giancarlo $u Department of Surgical Sciences, San Giovanni Battista Hospital and University of Turin, Turin, Italy
700    1_
$a Tilki, Derya $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg Eppendorf, Hamburg, Germany. d.tilki@uke.de $u Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany. d.tilki@uke.de $u Department of Urology, Koc University Hospital, Istanbul, Turkey. d.tilki@uke.de $1 https://orcid.org/0000000170331380
773    0_
$w MED00008064 $t Prostate cancer and prostatic diseases $x 1476-5608 $g Roč. 27, č. 4 (2024), s. 686-692
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37803241 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104258 $b ABA008
999    __
$a ok $b bmc $g 2263244 $s 1239361
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 27 $c 4 $d 686-692 $e 20231006 $i 1476-5608 $m Prostate cancer and prostatic diseases $n Prostate Cancer Prostatic Dis $x MED00008064
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace